<DOC>
	<DOCNO>NCT00428714</DOCNO>
	<brief_summary>The purpose see quickly two different type prostate cancer patient respond take enzastaurin . Cohort 1 - asymptomatic patient androgen-independent PSA-progressive disease without clinical radiographic evidence metastatic disease . Cohort 2 - patient androgen-independent metastatic prostate cancer ( document bone soft tissue metastasis ) rise PSA , clinical , radiographic disease progression follow one prior docetaxel-based regimen</brief_summary>
	<brief_title>Phase 2 Trial Enzastaurin Prostate Cancer Patients Who Have Had Hormonal Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>You expect alive 12 week . You least 18 year old . You live close enough doctor 's office attend require visit . You treat chemotherapy prostate cancer ( cohort 1 ) . You one prior docetaxelbased chemotherapy regimen ( cohort 2 ) . You evidence metastatic prostate cancer bone soft tissue disease ( cohort 2 ) . Your organ must function properly . You unable swallow pill . You another illness besides prostate cancer . You take another experimental drug within last 30 day . You serious heart condition . You receive another anticancer therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>